Professor, Head & Neck Surgery & Director of Perioperative Surgical Services. Expert in neoadjuvant trials. Husband, father and outdoor enthusiast.
Houston, TX
Joined May 2016
- Tweets1.7K
- Following887
- Followers2K
- Likes3.5K
Pinned Tweet
🗞️ today in @Nature! Incredible work led by @moranamit2 #OncSurgery @MDAndersonNews translating our findings using #neoadjuvant #immunotherapy in #skin #CSCC cancer @AACR @NEJM into a novel understanding of cancer biology. nature.com/articles/s41586-0…
Neil D. Gross, MD, FACS retweeted
See the full schedule: spr.ly/6011BHbJuX #ESMO26 #EndCancer 2/2
@AmirJazaeri @ShannonWestin @HTawbi_MDPhD @DrNeilGross @LuanaGSousaMD @DrDavidHui @JenniferLitton @shgiordano
Neil D. Gross, MD, FACS retweeted
At #ESMO26, @DrNeilGross discusses the final analysis of neoadjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma, and what a trial would need to show before complete responders could skip surgery
@myESMO #CSCC #SkinCancer #SkcSM @UTMDAnderson
Breaking News! 🗞️ Published today in @JCO_ASCO and presented simultaneously at @myESMO. Long-term survival remains excellent 📈 after #neoadjuvant #Immunotherapy for advanced resectable @SquamousCscc #skincancer. #OncSurgery #EndCancer @UTMDAnderson
ascopubs.org/doi/10.1200/JCO…
Neil D. Gross, MD, FACS retweeted
UT MD Anderson researchers discovered that psilocybin given before chemotherapy prevented the onset of nerve injury in preclinical models, which could help prevent common chemotherapy side effects: spr.ly/6018BGHocs @moranamit2 #EndCancer
So proud of the huge efforts led by @moranamit2 to help unlock the biology of non-melanoma #skincancer in immunosuppressed patients! @ShorookNa #OncSurgery @MDAndersonnews 🗞️
Cell cell.com/cell/fulltext/S0092…
Neil D. Gross, MD, FACS retweeted
UT MD Anderson researchers discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells, but those cells have lost the ability to communicate effectively.
spr.ly/6016B18WwK @moranamit2 @raikunal @PriyathersiniN #EndCancer
Neil D. Gross, MD, FACS retweeted
Maura L. Gillison, MD, PhD, a medical oncologist and molecular epidemiologist whose work changed the standard of care for head and neck cancer by distinguishing human papillomavirus-positive from HPV-negative disease and thereby guiding diagnosis, treatment and prevention, died on June 21.
@UTMDAnderson
cancerletter.com/obituary/20…
Neil D. Gross, MD, FACS retweeted
Vale Richard.
I am deeply saddened to lose such a cherished colleague. Richard was a truly extraordinary pathologist - the 'pathologists' pathologist' - who also made generous time for clinicians navigating complex diagnostic cases, understanding that an accurate tissue diagnosis was critical to patient care. His knowledge was vast, his skill exceptional, with an unparalleled eye for accurate tissue diagnoses, and the precision to apply decades of experience where it mattered most.
He shared his expertise widely: through consultation on external specimens, through diagnostic and classification frameworks now used worldwide, and as a devoted teacher and mentor. Richard has left an indelible mark on all who had the privilege of working alongside him.
My thoughts are with Richard's family during this difficult time, particularly his wife Katie and children Emily, Matthew, and Lucy.
See tribute on @MelanomaAus website > melanoma.org.au/news/vale-ri…
Neil D. Gross, MD, FACS retweeted
There are places in healthcare where excellence is visible… and others where it is absolutely essential, yet rarely seen.
Today, the @UTMDAnderson Chairs of Surgery and Perioperative leadership toured sterile processing. Pure discipline in repetition, the SPD team quietly shapes every surgical outcome long before incision. There is no high-performing OR without a high-performing SPD.
A sincere thank you to Brian Rago, Director Ad Interim, Gwendolyn Carter, SPD Ops Manager, for their operational strength and commitment to team development.
And to the SPD service line leads driving daily excellence:
Jacob Mathew – Plastics / Head & Neck
Ranissia Harris – GGTP / Surgical Oncology / CRS
Marcesha Franklin – Neuro
Denise Turner – Ortho
Your work is not just supporting surgery, it is enabling it. This is what modern sterile processing looks like: data-driven, team-centered, and relentlessly focused on safety. Grateful for this team.
#SterileProcessing #Oncsurgery #WeFightDirty
Neil D. Gross, MD, FACS retweeted
Not sure how many people have noticed this: In the latest (Mar 4) release of 24 new research papers from Nature (top science journal), 8 came from the US and 8 came from China. nature.com/nature/research-a… Among the 29 new research papers in Cell (top journal in biomedical sciences) released this year, 8 came from the US while 10 came from China. cell.com/cell/newarticles Meanwhile US labs are suffering from the aftermath of the NIH/NSF funding disruptions - including drastically reduced funding rates and as a result diminishing lab sizes and competitiveness in #STEM research.
Neil D. Gross, MD, FACS retweeted
The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system
nature.com/articles/s41591-0…
Incredible. Congratulations!
Humbled and happy to announce that I’ve been selected as a shortlisted finalist in oncology for the 2026 Takeda Innovators in Science Award with Nature Portfolio. @OncoAlert @NKI_nl @DrChoueiri @NaturePortfolio @TakedaOncology
nature.com/immersive/innovat…
Neil D. Gross, MD, FACS retweeted
Excited, happy and proud to share our @Nature publication on neoadjuvant ICB in pMMR colon cancer; #NICHE! We provide validation of previous clinical results, plus extensive and comprehensive analyses of Overdue tweetorial below❗️ nature.com/articles/s41586-0…
Neil D. Gross, MD, FACS retweeted
Thrilled to share our paper published in Nature Cancer, alongside the JAVELIN-100 sister study. Our work identifies intratumoral bacterial burden as a key determinant of immunotherapy response in HNSCC. Thanks to the team who made this possible.
🔗 nature.com/articles/s43018-0…
Neil D. Gross, MD, FACS retweeted
Thank you Nature Cancer for highlighting our work! @GeneCollector @TylerAlban1 @xrtGenomics @DrNeilGross @CleClinicNews @ClevelandClinic
🎆New year, new papers at Nature Cancer!
The amount of tumor bacteria is now shown to influence immunotherapy outcomes in head and neck cancer in two papers out today:
🔗nature.com/articles/s43018-0…
🔗nature.com/articles/s43018-0…
With the associated N&Vs:
nature.com/articles/s43018-0…
Neil D. Gross, MD, FACS retweeted
🎆New year, new papers at Nature Cancer!
The amount of tumor bacteria is now shown to influence immunotherapy outcomes in head and neck cancer in two papers out today:
🔗nature.com/articles/s43018-0…
🔗nature.com/articles/s43018-0…
With the associated N&Vs:
nature.com/articles/s43018-0…
Happy New Year 🥳 to the patients, their families, sites and investigators of #C-PRE @NCICancerCtrl @NRGonc #HN014. Tremendous progress in 2025….ACCRUAL = 80! @TROGfightcancer @CDNCancerTrials #OncSurgery @MDAndersonNews
Great to be @ClevelandClinic for #headandneck #cancer research update and to see @MDAndersonNews former fellow ‘besties’ Dr. Jamie Ku and @nataliesilvermd crushing it! 🧬🩺
Another great month of accrual to #HN014! Thanks to the patients, their families, sites and investigators. 🙏 @NRGonc @NCICancerCtrl @TROGfightcancer @CDNCancerTrials #OncSurgery @MDAndersonNews
Congratulations to @drsydneychng @COBLH @TROGfightcancer for being the first 🇦🇺 site to enroll to #HN014 #C-PRE @NRGonc @NCICancerCtrl
@CDNCancerTrials @Regeneron #neoadjuvant #OncSurgery @MDAndersonNews
